Mangoceuticals Reports 38% Revenue Decline in Q1 2026, Net Loss Improves

Mangoceuticals, Inc. reported a revenue of $67,864 for the first quarter of 2026, a decline of approximately 38% compared to $109,306 in the same period of 2025. The decrease in revenue is attributed to the company's focus on in-house website development and the testing of new testosterone replacement therapy (TRT) products in select markets prior to their full launch. The cost of revenues also saw a significant reduction, dropping to $8,218 from $24,737 year-over-year, primarily due to fluctuations in third-party service provider usage and product promotions.

The company's operating expenses decreased to $3,155,327 for the first quarter of 2026, down from $4,638,438 in the prior year. This reduction was driven by lower general and administrative expenses, which fell to $1,054,122 from $1,542,444, and a significant decrease in investor relations expenses, which dropped from $1,419,000 to $12,451. Despite these reductions, stock-based compensation increased to $1,647,821 from $1,045,479, reflecting the issuance of stock for services rendered. The net loss for the quarter was $3,403,141, an improvement from the $4,839,489 loss reported in the same quarter of 2025.

Mangoceuticals has been actively pursuing strategic developments, including the launch of its telemedicine platform and various men's wellness products. The company is in the process of conducting Phase II clinical trials for its patented respiratory illness prevention technology and has entered into a Master Distribution Agreement with Propre Energie, Inc. to market plant-based formulations targeting skin conditions. Additionally, the company has expanded its operations internationally, with subsidiaries established in Mexico and the UK.

As of March 31, 2026, Mangoceuticals reported total assets of $14,449,223 and total liabilities of $974,571, resulting in a working capital deficit of approximately $0.5 million. The company had cash and cash equivalents of $174,562, a significant decrease from $1,486,338 at the end of 2025. The company anticipates needing additional funding to support its operations and growth strategy, which may involve raising capital through equity or debt financing. The management has expressed concerns about the ability to continue as a going concern if additional funding is not secured.

Looking ahead, Mangoceuticals plans to continue its marketing efforts and expand its product offerings while exploring potential acquisitions to enhance its growth. The company is also focused on improving its technology platform and customer experience. However, the need for additional funding remains a critical factor in executing its business plan, and the management has indicated that the current capital resources may not be sufficient to sustain operations for the next 12 months without further financing.